By rray, 6 May, 2024 Refer pt for tx of other disorders or functional issues e g relationship distress
By rray, 6 May, 2024 If pt wishes to continue pharmacotherapy investigate and discuss continuing meds w behavioral health or primary care
By rray, 6 May, 2024 Before end of psychopharmacology discuss risks and benefits of discontinuing meds including possible side effects and sx return Make tapering schedule based on pt preference discuss length of time required and anticipated life events and stressors Discuss
By rray, 6 May, 2024 End PTSD tx or taper based on clinician judgment and pt preference normalize sx fluctuations discuss self monitoring for sx that warrant future attention and provide resources for seeking care in the future
By rray, 6 May, 2024 See the VA DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide
By rray, 6 May, 2024 After sufficient time has passed for a clinically meaningful response reassess PTSD sx diagnostic status functional status QOL additional tx and support needs and pt preferences
By rray, 6 May, 2024 Clinically meaningful response times nbsp nbsp Psychotherapies Initial tx effects typically noticeable after 4 8 sessions over 8 12wk Need adequate dosage to be fully effective might have attenuated effect if delivered less than weekly nbsp nbsp Pharmacot
By rray, 6 May, 2024 If persistent 1mo or worsening traumatic stress sx or high risk for developing PTSD assess for PTSD